logo
MDA Space and SatixFy Announce Amended Merger Agreement for Increased Consideration and Postponement of Shareholder Meeting

MDA Space and SatixFy Announce Amended Merger Agreement for Increased Consideration and Postponement of Shareholder Meeting

BRAMPTON, ON, May 20, 2025 /CNW/ – MDA Space Ltd. (TSX: MDA), a trusted mission partner to the rapidly expanding global space industry, and SatixFy Communications Ltd. (NYSE American: SATX), a leader in next-generation satellite communication systems based on in-house-developed chipsets, today announced that they have agreed to amend the terms of the Agreement and Plan of Merger (the 'Merger Agreement'), dated April 1, 2025 among SatixFy Communications Ltd. ('SatixFy') , MDA Space Ltd. ('MDA') and certain subsidiaries, pursuant to which MDA agreed to acquire SatixFy in an all-cash transaction for US$2.10 (without interest) per ordinary share, which implied an aggregate equity value for the Company of approximately US$193 million.
The amendment follows a go-shop process, conducted by SatixFy with the assistance of its financial advisor TD Securities (USA) LLC, in which approximately 75 third parties were contacted to determine whether they had an interest in making an Acquisition Proposal (as such term is defined in the Merger Agreement). The 'go-shop' period under the Merger Agreement expired at 11:59 p.m. ET on May 16, 2025.
As a result of this process, SatixFy received during the 'go-shop' period an Acquisition Proposal from a third-party (the 'Go-Shop Party' and the 'Go-Shop Proposal', respectively) to acquire all of the outstanding shares of SatixFy in an all-stock transaction, consisting of a number of the Go-Shop Party's shares that would imply aggregate equity consideration of approximately US$233.5 million, or approximately US$2.53 per ordinary share. Furthermore, the exchange ratio, on the basis of which the consideration pursuant to the Go-Shop Proposal would be calculated, featured a collar such that the ratio between the SatixFy shares and the Go-Shop Party stock consideration would remain fixed despite any increase in the Go-Shop Party's trading price to enable the holders of SatixFy's ordinary shares to participate in up to a 10% increase, and would be adjusted in the event of any decrease in the Go-Shop Party's trading price to enable the holders to receive the same aggregate value of US$233.5 million despite up to a 20% decrease. MDA disputed the validity of SatixFy's notice of the Acquisition Proposal.
In response to the Go-Shop Proposal and subsequent discussions with MDA, SatixFy and MDA reached an agreement to amend the Merger Agreement to provide for a significant increase in the merger consideration to an all-cash transaction for US$3.00 (without interest) per ordinary share, which implies an aggregate equity value for the Company of approximately US$280 million. The increase in the merger consideration is based upon the commitment by the Company not to consider any other acquisition proposals for SatixFy and for SatixFy's Board of Directors (the 'Board') not to change its recommendation supporting the Merger Agreement, as amended.
The Board determined that the increased price per share is the best value for the shareholders of Satixfy, after taking into account various considerations including time to close and risks of delays, risks to closing, financial situation of the company, benefits of an all-cash transaction and others (the 'Board Determination').
The Board unanimously reiterates its recommendation that SatixFy shareholders vote FOR the revised transaction at the Meeting (as defined below).
Shareholders holding approximately 57% of SatixFy outstanding shares have entered into voting support agreements pursuant to which they have committed to vote in favor of the transaction.
In connection with the Board Determination, the Board also resolved that the upcoming Special General Meeting of Shareholders to approve the Merger Agreement and related transactions which was scheduled for May 20, 2025 will be postponed to 4:00 p.m. Israel time on May 23, 2025 to allow sufficient time under applicable laws, rules and regulations for the announcement and distribution of the disclosures set forth herein. There is currently no change to the location, the record date, the purpose or any of the proposals to be acted upon at the Special General Meeting of Shareholders, except as set forth in this press release.
Forward-Looking Statements
This news release contains forward‐looking information within the meaning of applicable securities legislation, which reflects MDA Space's and SatixFy's current expectations regarding future events.
Forward-looking statements in this news release include, but are not limited to, statements with respect to: the consideration to be received by SatixFy's shareholders; the go-shop process during the Go-Shop Period (as defined in the Merger Agreement); compliance by MDA Space and SatixFy with various covenants contained in the Merger Agreement; the receipt of regulatory approvals and the satisfaction of the closing conditions of the transaction; and the anticipated timing for SatixFy's shareholders' meeting and completion of the transaction. In particular, there can be no assurance that the Transaction will be completed on the terms described herein, if at all.
Forward‐looking information is based on a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond the control of MDA Space and SatixFy, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward‐looking information, including: approvals required in connection with the transaction; compliance with the voting support agreements; the satisfaction or waiver of the closing conditions of the transaction (if at all); adverse changes in applicable laws or regulations; delay or inability of MDA Space to pay the consideration contemplated by the Merger Agreement; expected growth; results of operations; performance; industry trends and growth opportunities. While MDA Space and SatixFy consider these assumptions to be reasonable, based on information currently available, they may prove to be incorrect. Additional risks and uncertainties applicable to MDA Space include, but are not limited to, the factors discussed under 'Risk Factors' in the MDA Space Annual Information Form (AIF) dated March 7, 2025 and available on SEDAR+ at www.sedarplus.com. Additional risks and uncertainties applicable to SatixFy include, but are not limited to, the factors discussed under 'Risk Factors' in SatixFy's Annual Report on Form 20-F for the year ended December 31, 2024 filed with the SEC on April 1, 2025, as amended, and other documents filed with or furnished to the SEC which are available on the SEC's website, www.sec.gov. Neither MDA Space nor SatixFy undertakes any obligation to update such forward‐looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.
In connection with this transaction, SatixFy has submitted a proxy statement and form of proxy card to the SEC. Investors are urged to read these materials carefully because they contain important information about SatixFy and this transaction subject to the amendments contemplated referenced herein. The proxy statement, proxy card and certain other relevant materials and any other documents submitted by SatixFy to SEC may be obtained free of charge at the SEC's website at http://www.sec.gov. Investors are urged to read the proxy statement and the other relevant materials carefully before making any voting or investment decision with respect to this transaction.
ABOUT MDA SPACE Building the space between proven and possible, MDA Space (TSX:MDA) is a trusted mission partner to the global space industry. A robotics, satellite systems and geointelligence pioneer with a 55-year+ story of world firsts and more than 450 missions, MDA Space is a global leader in communications satellites, Earth and space observation, and space exploration and infrastructure. The MDA Space team of more than 3,400 space experts in Canada, the US and the UK has the knowledge and know-how to turn an audacious customer vision into an achievable mission – bringing to bear a one-of-a-kind mix of experience, engineering excellence and wide-eyed wonder that's been in our DNA since day one. For those who dream big and push boundaries on the ground and in the stars to change the world for the better, we'll take you there. For more information, visit www.mda.space.
ABOUT SATIXFY SatixFy develops chips and systems that serve the full satellite communication value chain from gateways through payload subsystems and terminals. Our cutting-edge space grade chipset supports next-generation satellite communications systems, including satellite multi-beam digital space antennas, space processors flat panel user terminals and modems, based on powerful in-house designed chipsets. SatixFy's products include modems that feature Software Defined Radio (SDR) and Fully Electronically Steered Multi Beam Antennas (ESMA) that support the advanced communications standard DVB-S2X and RCS2. SatixFy's innovative ASICs improve the overall performance of satellite communications systems, reduce the weight and power requirements of terminals and payloads, and save real estate for gateway equipment. SatixFy's advanced VSATs and multi-beam fully electronically steered antenna arrays are optimized for a variety of mobile applications and services, prepared for multi-orbits LEO, MEO and GEO satellite communications systems, for aero/in-flight connectivity systems, communications-on-the-move applications and more. For more information, please visit www.SatixFy.com.
SOCIAL MEDIALinkedIn: linkedin.com/company/mdaspaceX: twitter.com/MDA_space Facebook: facebook.com/MDAspaceYouTube: youtube.com/c/mdaspaceInstagram: instagram.com/MDA_space

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

AI agent adoption rates are at 50% in tech companies. Is this the future of work?
AI agent adoption rates are at 50% in tech companies. Is this the future of work?

The Star

time4 hours ago

  • The Star

AI agent adoption rates are at 50% in tech companies. Is this the future of work?

Agent AI is, for the moment, one of the most advanced forms of the new technology, in which agents informed by AI can carry out more complex tasks than the large language model chatbot tools. — Pixabay Artificial intelligence use in the workplace keeps growing, and it's no surprise the tech sector is a leader in harnessing those tools. But a new report from the accounting and consulting giant EY makes clear just how quickly the industry has gotten onboard the AI train. The firm quizzed senior executives and found incredibly positive sentiment toward AI and its promise for helping companies grow, with nary a hint of the kind of doubts found in other recent reports. You may think it's obvious that tech firms think they'll benefit from AI – after all, Google has said it will spend US$100bil (RM425.60bil) on next-gen tech, and certainly expects to reap the benefits of that investment. Microsoft, Meta, OpenAI, and others have revealed similar plans. But the point is, it's not just the big names with big investments that feel this way. And in our technology-centric world, tech firms blaze a trail that other industries then follow. EY's Technology Pulse Poll surveyed over 500 senior technology company leaders – and reported that nearly half of them said they were already fully deployed or were in the process of adopting agent AI tech into their company. Agent AI is, for the moment, one of the most advanced forms of the new technology, in which 'agents' informed by AI can carry out more complex tasks than the large language model chatbot tools popularised by OpenAI's ChatGPT application. Big service providers like Salesforce, Google, and numerous other firms are now in the early phases of rolling out what OpenAI's CEO Sam Altman has heralded as the next generation of AI tools. The executives EY spoke to are putting their money where their mouths are. A whopping 92% expect to actually increase the amount they spend on AI over the next year – a 10% point rise from 2024. This effectively means nearly every tech executive in the survey plans to spend more on AI in the near future, a clear sign that whatever experimental phase agent AI was in is over, and the tech has been widely accepted despite bumps in its development. We're far beyond snake oil territory with that kind of leadership buy-in. Ken Englund, technology sector growth leader at EY, confirmed in an email interview with Inc. that he believes this AI funding is 'coming from the reprioritisation of existing programs and some operational efficiencies at technology organisations.' Essentially, last year leaders spent a little on AI as part of 'pilots and proof of concepts,' Englund thinks. This year, the spending is the real thing. The spending increase may be driven by these leaders' general enthusiasm for AI, which has attracted billions in investment capital and is already reshaping the landscape with the massive data centers needed to power it. EY found 81% were optimistic about the tech's potential to help their company reach its goals in the next year. And nearly six in 10 survey respondents said they believed their organisation was ahead of competitors in AI investment. EY notes that this may signal a 'clear shift' toward prioritising AI in long-term business planning. Again, this level of executive buy-in is beyond mere 'keeping up with the Joneses' investment levels, which would try to ensure their company isn't left behind the leading edge of the newest technology craze. The positive sentiment from tech executives certainly runs counter to recent research –including data from tech giant Lenovo, which suggested the one thing keeping companies from maximising the potential benefits from AI tech deployments was hesitancy from company leadership. Fully 55% of IT leaders surveyed by Lenovo said a 'lack of vision' on digital workplace transformation is on their lists of the top three obstacles preventing access to greater AI benefits. It's understandable from a C-suite perspective – this transformation is essentially a total reimagining of many workplace norms, which the experts say is needed if AI is to really bring a return on investments. Englund also partly addressed this issue, noting that 'The prevailing mindset among executives is that agentic AI will be a positive-sum scenario in which productivity will drive net-new growth,' he said. 'Certainly, they expect efficiencies in existing work processes,' adding that 'agentic AI will likely create entirely new workflows in an enterprise.' This may even include replacing, reskilling, or repositioning the leadership team itself, of course. Lastly, reskilling and upskilling of workers has been something other reports suggest will be necessary as AI hits the workplace. EY's data shows tech leaders are conscious of this issue. Seventy percent of those surveyed were 'focusing on upskilling,' while 68% were 'hiring AI-skilled talent.' More positively, only 9% were planning on layoffs in the next six months, implying, perhaps, that AI isn't outright replacing many workers yet. Why should you care about this? For one main reason: If tech leaders are leading the AI charge, other companies in other sectors will follow in their wake once the benefits of AI tech are proven. EY's report contains such a positive vibe about AI that it stands out against other more dystopian AI reporting, and counters data showing about half of US workers worry they'll lose their job to AI. – Inc./Tribune News Service

Biomarkers Market worth US$104.15 billion in 2030 with 10.8% CAGR
Biomarkers Market worth US$104.15 billion in 2030 with 10.8% CAGR

Malaysian Reserve

time4 hours ago

  • Malaysian Reserve

Biomarkers Market worth US$104.15 billion in 2030 with 10.8% CAGR

DELRAY BEACH, Fla., May 30, 2025 /PRNewswire/ — The global Biomarkers Market, valued at US$58.07 billion in 2024 stood at US$62.39 billion in 2025 and is projected to advance at a resilient CAGR of 10.8% from 2025 to 2030, culminating in a forecasted valuation of US$104.15 billion by the end of the period. This growth is supported by the growing use of biomarkers in drug development and the increasing role of companion diagnostics in advancing precision medicine. The rising number of cancer cases worldwide and increased funding for various types of research are other important factors propelling the market's growth. Moreover, advances in omics technologies, including genomics and proteomics, are now enabling the development of more sophisticated tests based on biomarkers. Many companies are now targeting new markets such as the Asia Pacific region, where there is a high demand for targeted diagnostics, thus creating new opportunities for biomarker-driven solutions. Download PDF Brochure: Browse in-depth TOC on 'Biomarkers Market' 700 – Tables54 – Figures510 – Pages By offering, the biomarkers market is categorized into consumables, services, and software. Consumables are further sub segmented into assay kits, reagents & chemicals, and columns & filters. The consumables segment accounted for the largest share of the global biomarkers market in 2024. The large share of consumables is due to the high and recurring demand for assay kits, reagents, and other consumables in biomarker-based research, diagnostics, and validation workflows, which ensures continuous usage across laboratories and clinical settings. Additionally, the growing number of biomarker-based studies and clinical trials has driven the need for reliable, high-throughput consumables that support reproducibility and scalability. Moreover, the increasing adoption of multiplex assay platforms, which require specialized consumables to detect multiple biomarkers from limited sample volumes, also supports the large share of the consumables segment. By type, the biomarkers market is categorized into safety, efficacy, and validation biomarkers. The efficacy biomarkers are sub segmented into predictive, surrogate, pharmacodynamics, and prognostic biomarkers. The safety biomarkers segment held the largest share in the biomarkers market in 2024. This can be attributed to the use of safety biomarkers in drug development to assess toxicity and identify potential adverse effects early in the development process. Regulatory agencies increasingly require safety biomarkers to ensure drug candidates meet safety standards before advancing to later stages of clinical trials. Additionally, pharmaceutical companies are investing in safety biomarker strategies to reduce the risk of late-stage failures and improve decision-making during preclinical and early clinical phases. By PCR technology, the biomarkers market is segmented by technology into immunoassays, NGS, PCR, mass spectrometry, chromatography, and other technologies. PCR technology, which is used for detecting, quantifying, and validating nucleic acid-based biomarkers, is estimated to register the highest CAGR during the forecast period of 2025-2030. This growth is supported by this technology's high sensitivity, cost-effectiveness, and broad applicability in detecting and quantifying genetic material. Companies can utilize this growth by expanding PCR-based test offerings, developing multiplex PCR kits, and integrating PCR platforms into biomarker-based diagnostics and companion tests. While PCR is expected to lead in growth, companies can also benefit from incorporating other technologies, such as NGS and MS, to support comprehensive biomarker analysis, particularly where high-throughput sequencing or protein-level insights are required. By geography, the biomarkers market is segmented into North America, Europe, Asia Pacific (APAC), Latin America (LATAM), the Middle East, and Africa. In 2024, North America held the largest share in the biomarkers market due to its well-established healthcare infrastructure, high research and development spending, and strong presence of leading pharmaceutical and biotechnology companies. The region has a high adoption rate of advanced technologies, including next-generation sequencing and companion diagnostics, which support biomarker discovery and application across clinical and research settings. Additionally, favorable regulatory frameworks, availability of funding from government and private sources, and a growing focus on precision medicine have further driven the use of biomarkers. The increasing burden of chronic diseases such as cancer and cardiovascular conditions has also contributed to sustained demand for biomarker-based diagnostics and therapies in the region. Request Sample Pages : Key players in the biomarkers market include F. Hoffmann-La Roche Ltd (Switzerland), Merck KGaA (Germany), Thermo Fisher Scientific Inc. (US), Abbott (US), QIAGEN (Netherlands), Revvity (US), Laboratory Corporation of America Holdings (US), Charles River Laboratories (US), Bio-Rad Laboratories, Inc. (US), Eurofins Scientific (Luxembourg), BIOMÉRIEUX (France), Agilent Technologies, Inc. (US), and JSR Corporation (Japan). The market includes many other prominent companies and competitive startups/SMEs. F. Hoffmann-La Roche Ltd (Switzerland): F. Hoffmann-La Roche Ltd is a major player in the global biomarker market, leveraging its integrated diagnostics-pharmaceutical business model, strong geographical presence, and ongoing innovation. The company operates in two segments: Diagnostics and Pharmaceuticals, with the Diagnostics division encompassing Core Lab, Molecular Lab, Pathology Lab, Point of Care, and Diabetes Care. These divisions provide biomarker-based assays, digital platforms, and companion diagnostics for applications in oncology, cardiology, neurology, infectious diseases, and diabetes. In 2023, Roche's Diagnostics division processed over 29 billion tests across more than 100,000 platforms, reflecting strong global demand. The company launched over 20 diagnostic assays between 2022 and May 2025, including the FDA-approved VENTANA MET (SP44) RxDx Assay for non-squamous non-small cell lung cancer. Roche also actively pursues partnerships, such as collaborations with PathAI for AI-based pathology algorithms and with Neuron23 to utilize digital biomarkers in Parkinson's disease trials. Roche's integration of diagnostic development, test delivery, and data platforms, along with its global reach and AI-enabled R&D, enhances its leadership in the biomarker market. Merck KGaA (Germany) Merck KGaA is a major player in the biomarker market through its Life Science segment, which provides biomarker assays, consumables, software, and services for research and diagnostics. The Science & Lab Solutions division focuses on biomarker discovery, validation, and analysis. With a global presence and subsidiaries like EMD Millipore Corporation and Merck Biosciences AG, Merck has strengthened its position through strategic partnerships. In January 2025, it collaborated with Qpentions Labworks to automate assay workflows with the Flex robotic workstation, enhancing protein sample preparation. Additionally, in June 2024, Merck partnered with the Michael J. Fox Foundation to support the SMCXPRQ immunoassay platform for detecting low-abundance biomarkers related to early Parkinson's disease. This focus on automation and disease-specific advancements highlights Merck's significant role in the global biomarker market. For more information, Inquire Now! Related Reports: Cancer Biomarkers Market Cardiac Marker Testing Market Cancer Profiling Market Companion Diagnostics Market PCR Technologies Market Get access to the latest updates on Biomarkers Companies and Biomarkers Market Size About MarketsandMarkets™: MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit or follow us on Twitter, LinkedIn and Facebook. Contact:Mr. Rohan SalgarkarMarketsandMarkets™ INC.1615 South Congress 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: sales@ Our Website: Logo: View original content:

Stocks unsettled after Trump accuses China of trade deal breach
Stocks unsettled after Trump accuses China of trade deal breach

New Straits Times

time5 hours ago

  • New Straits Times

Stocks unsettled after Trump accuses China of trade deal breach

NEW YORK: Global stocks finished mixed on Friday after President Donald Trump put US-China trade tensions back on the boil by claiming Beijing had "totally violated" an agreement with Washington. His social media post came hours after US Treasury Secretary Scott Bessent said trade talks with China aimed at putting to bed sky-high mutual tariffs – currently suspended – were "a bit stalled." The development risks renewed trade tensions between the world's two biggest economies. On Wall Street, the Dow Jones Industrial Average closed higher, while the S&P 500 index was flat, and the tech-focused Nasdaq Composite fell 0.3 per cent. "If it weren't for the trade war, the market would be feeling pretty good," said Tom Cahill of Ventura Wealth Management. "Inflation is definitely moving in the right direction," he added, referencing the Federal Reserve's favoured inflation gauge, which cooled more than expected last month, according to fresh data published Friday. In Europe, London and Germany's major indices ended higher, while France's CAC40 closed lower, following declines in Asian markets earlier in the day. "If President Trump does slap tariffs back on Chinese imports to the US... we may see demand for US assets, and the dollar, severely impaired by a chaotic and undiplomatic approach to trade policy," said Kathleen Brooks, research director at XTB. Despite rumbling concerns about the US-China economic relationship, the markets were little changed by Trump's criticism on social media, with investors appearing to be largely inured to the US president's now-familiar cycle of making dramatic trade threats and then retreating. Investors, traders and analysts instead focused on the Commerce Department's personal consumption expenditures (PCE) price index data, which rose 2.1 per cent in the 12 months to April – cooling slightly more than expected. Despite the good news for the Fed, which is looking to bring inflation down to its long-term target of two per cent, analysts warned that the fuller inflationary effects of Trump's tariffs were yet to come, and could cause the Fed to maintain its watch-and-wait stance. "The true weight of these policies is likely to emerge more fully in the months ahead," said market analyst Fawad Razaqzada. Investors were also assessing the impact of a US court ruling that invalidated most of Trump's sweeping tariffs – though an appeals court suspended that order and the White House vowed that its tariffs goals would be pursued one way or another. The result leaves Trump's tariff plans in something of "a legal limbo" said Stephen Innes, of SPI Asset Management, adding that this sort of legal impasse was "the kind that keeps traders awake at night." In the eurozone, interest rates were in focus after official data showed inflation hovering around the European Central Bank's two-per cent target. Consumer prices in top EU economy Germany showed a 2.1 per cent rise in May – the same as the previous month – while they fell to 1.9 per cent in Spain, and to 1.7 per cent in Italy. The ECB looks set to lower interest rates again on Thursday. The dollar gained against major currencies, while oil prices were down ahead of a Saturday meeting of eight key OPEC+ members to decide production quotas for July, with some analysts predicting that the cartel could make a larger-than-expected supply hike. New York - Dow: UP 0.1 per cent at 42,270.07 points (close) New York - S&P 500: DOWN less than 0.1 per cent at 5,911.69 (close) New York - Nasdaq Composite: DOWN 0.3 per cent at 19,113.77 (close) London - FTSE 100: UP 0.6 per cent at 8,772.38 (close) Paris - CAC 40: DOWN 0.4 per cent at 7,751.89 (close) Frankfurt - DAX: UP 0.3 per cent at 23,997.48 (close) Tokyo - Nikkei 225: DOWN 1.2 per cent at 37,965.10 (close) Hong Kong - Hang Seng Index: DOWN 1.2 per cent at 23,289.77 (close) Shanghai - Composite: DOWN 0.5 per cent at 3,347.49 (close) Euro/dollar: DOWN at US$1.1349 from US$1.1368 on Thursday Pound/dollar: DOWN at US$1.3463 from US$1.3494 Dollar/yen: DOWN at 143.97 yen from 144.19 yen Euro/pound: UP at 84.30 pence from 84.22 pence

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store